Impax Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Impax Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,049	Closed	-$200K	–	213
2015 Q4	$200K	Buy	+1,049	New	+$183K	0.01%	191
2015 Q3	–	Sell	-8,415	Closed	-$1.52M	–	201
2015 Q2	$1.52M	Buy	8,415 +7	+0.1%	+$1.21K	0.08%	149
2015 Q1	$1.46M	Sell	8,408 -1,621	-16%	-$293K	0.08%	154
2014 Q4	$1.86M	Buy	10,029 +60	+0.6%	+$11.1K	0.11%	149
2014 Q3	$1.65M	Sell	9,969 -95	-0.9%	-$15.6K	0.11%	142
2014 Q2	$1.57M	Hold	10,064	–	–	0.1%	142
2014 Q1	$1.53M	Buy	10,064 +2	+0%	+$318	0.1%	138
2013 Q4	$1.34M	Sell	10,062 -41	-0.4%	-$4.92K	0.08%	137
2013 Q3	$1.17M	Sell	10,103 -3,536	-26%	-$388K	0.08%	140
2013 Q2	$1.26M	Buy	+13,639	New	+$1.31M	0.09%	129

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Impax Asset Management's ALXN Position: Q1 2016 in Review

Impax Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 1,049 shares — an estimated $200K sold.

Impax Asset Management first reported a position in ALXN in Q2 2013 and held it in 10 quarters. The position peaked at $1.86M in Q4 2014. 520 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

Impax Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Impax Asset Management sold 1,049 Alexion Pharmaceuticals shares in Q1 2016, an estimated $200K.
Impax Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Impax Asset Management's Alexion Pharmaceuticals position peaked at $1.86M in Q4 2014.
520 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Impax Asset Management's 13F filing for Q1 2016, filed 11 May 2016.